Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience

<b>Background:</b> Immune checkpoint inhibitors (ICIs) have widened the therapeutic scenario of different solid tumors over the last ten years. Gastrointestinal (GI) adverse events (AEs), such as diarrhea and colitis, occur in up to 50% of patients treated with ICIs. <b>Materials and methods:</b> We...

Descripció completa

Dades bibliogràfiques

Autors principals:	Paola Parente, Brigida Anna Maiorano, Davide Ciardiello, Francesco Cocomazzi, Sonia Carparelli, Maria Guerra, Giuseppe Ingravallo, Gerardo Cazzato, Illuminato Carosi, Evaristo Maiello, Fabrizio Bossa
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2022-03-01
Col·lecció:	Diagnostics
Matèries:	immune checkpoint inhibitor ICI diarrhea colitis PD1 PD-L1
Accés en línia:	https://www.mdpi.com/2075-4418/12/3/685
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!